Nonviral nanoparticles have emerged as an attractive alternative to viral vectors for gene
therapy applications, utilizing a range of lipid‐based, polymeric, and inorganic materials …

Nanoparticles with oligonucleotides bound to the outside or incorporated into the matrix can
be used for gene editing or to modulate gene expression in the CNS. These nanocarriers …

Efficient methods for cell line transfection are well described, but, for primary neurons, a high-
yield method different from those relying on viral vectors is lacking. Viral transfection has …

Nucleic acid therapeutics can be used to control virtually every aspect of cell behavior and
therefore have significant potential to treat genetic disorders, infectious diseases, and …

With the development of genomic technologies, the prospect for gene therapy has
progressed rapidly. The major challenge of gene delivery is to improve the transfection …

Glioblastoma (GBM) is an aggressive central nervous system cancer with a dismal
prognosis. The standard of care involves surgical resection followed by radiotherapy and …

Nanocarriers are a new type of nonviral gene carriers, many of which have demonstrated a
broad range of pharmacological and biological properties, such as being biodegradable in …

Genetic medicine has great potential to treat the underlying causes of many human
diseases with exquisite precision, but the field has historically been stymied by delivery as …

Gene therapy is a novel technique that uses genetic material to prevent, treat, mitigate or
cure genetic and aquired diseases. Of the two methods, viral and non-viral gene delivery …

Background: Drug delivery across the blood-brain barrier (BBB) is a major limitation in the
treatment of central nervous system (CNS) disorders. Several approaches are being …